Merck is trading 3.1% up at $131.54 after winning FDA approval for Lipfendra, the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol in adults.

  • The approval allows Lipfendra to compete with existing injectable PCSK9 therapies, supported by strong Phase 3 clinical data.
  • Today's move extends a rally from Thursday and comes amid broader strength across the healthcare sector.